In skin cutaneous melanoma (SKCM), high SIGLEC9 expression correlated significantly with longer OS, progression-free interval, and disease-specific survival, while in hepatocellular carcinoma (HCC), SIGLEC9 overexpression on NK cells correlated with a worse prognosis [4,17]. Here, SIGLEC9 is linked to cutaneous melanoma.